Evotec to strengthen compound collection
Adds 110,000 diverse and lead-like compounds through ChemBridge collaboration
Evotec, a German developer of novel small molecule drugs with operational sites in Europe and Asia, is to collaborate with ChemBridge to further enhance its screening library.
San Diego-based ChemBridge is a global discovery chemistry company providing small molecule screening compound libraries, specialist building blocks for organic synthesis and custom chemistry services. The firm also operates a state-of-the-art offshore discovery chemistry research site in Moscow, Russia.
Through this collaboration, Evotec will increase its high throughput screening collection through the addition of initially 110,000 diverse and lead-like compounds from the ChemBridge Library Collection.
These new compounds complement the chemical diversity of Evotec’s existing collection of 250,000 drug-like and lead-like compounds and will further enhance the quality of the hits provided to its partners.
No financial details were disclosed.
